. 2016 Feb 18;5(6):e1145332. doi: 10.1080/2162402X.2016.1145332

Table 2.

Priority scores for glioblastoma immunotherapeutics with published clinical data.

							Immune checkpoints				Adoptive cellular
Therapeutic approach			CDX 110	TGF-βAnti-sense	HSP-96	EGFR Ab	Anti-CTLA-4	Anti-PD-1PD-L1	Anti-IL-2Rα	CSF-1R inhibitor	DCs	NK/LAK	CMV T cell	IL13Rα2CAR	IL-12
Antigen/ Target	Expression frequency	0–33% (1)34–66% (2)66–100 (3)	1^23-25	3¹²⁶	3^105,127	2^26,128,129		1¹⁰		1¹³⁰	3^15-17,131		3^15-17,131	3^132,133
	Benefit in other malignancy	1		1^134-136	0^14,137		1^47,138	1^48,139-144		1^59,60	1^145-147			1^148-150	1⁹⁴
	Homogeneous expression	1			1^105,127	1^26,128,129				1^57,151	1^16,17,131			1^132,133
	Persistence at recurrence	2	2^152,153	2¹²⁶		2^26,128,129		1⁹			2⁶⁵		2⁶⁵
	Mechanism of resistance	1	1^152,153			1^26,128,129
	Specificity of expression in the tumor	1	1^23-25								1^23-25			1^132,133
Immune activation and effector response	Immune activation	1	1^4,5		1¹²⁷	1¹⁵⁴	1^155-157				1^{22,31,34,35,37,38,40}		1⁶⁵	1¹⁵⁸	1^89-91
	Trafficking to the tumor	1	1¹⁵⁹		1¹⁰⁵		1^155-157	1⁸		1^58,160,161	1^{22,34,35,37,40}		1⁶⁵	1¹⁵⁸	1^89,91
	Maintenance of effector response within tumor	1			1¹⁰⁵		1^8,157	1^8,162			1^{22,34,35,37,40}			1¹⁵⁸	1⁸⁹
Agent:Preclinical	Anti-stem cell activity	2		2^163,164		2¹⁶⁵					2^166-168			2¹⁶⁹	2⁹²
	Efficacy in preclinical models	Other (1)Clone (1)Xenograft/*GEMM (2)	1^170,1712⁴	1^43-452¹⁶⁴		1¹⁶⁵2¹⁵⁴	2^{8,155,172,173}	2^8,162	1⁵³2¹⁷⁴	1^58,1601^58,1602^58,160	1²²1^{22,34,35,37,40}2²²	1^175-1772^178,179	1^61,65	1¹⁶⁹2¹⁵⁸	1^89,902^89,90,180
	Acceptable toxicity profile	2	2^4,159,181	2¹⁸²	2¹⁰⁵	2^154,183	2^47,184-190	2^{48,49,139-144}	2^54,174	2^58,60,160	2^{22,40,98,191-195}	2^62,63	2⁶⁵	2⁷⁰	2^90,93,196
	Hits target in vivo	2	2^4,197				2^8,172,173	2^8,162	2¹⁷⁴	2^58,160	2^22,37	2^178,179		2^158,169	2⁹⁰
Agent: Clinical	Clinical activity in GBM	3	3^27,29	3⁴⁶	3^104,105				3⁵⁴		3^22,30-35,98	3^62-64	3^60,64	3⁷⁰
	Extreme responders	2	2²⁹	2⁴⁵	2¹⁰⁴		2¹⁹⁸	2⁴⁸			2^22,30,31		2^60,64
	Combinatorial data	2	2^28,29		2¹⁰⁴	0^183,199	2⁵¹		2⁵⁴		2^22,30-33		2⁶¹
	Acceptable phase I safety data	2	2^159,181	2^46,200	2¹⁰⁵	2^183,199	2^{47,138,184-190}	2^{48,49,139-144}	2⁵⁴	2⁶⁰	2^22,30-33	2^62-64	2⁶⁵	2⁷⁰	2⁹⁴
Score			23	20	18	16	16	15	14	14	30	12	19	23	15

Abbreviation: *GEMM, genetically-engineered murine model (of glioma).